Strategy Inc filed an 8-K current report on August 10, 2026, disclosing updates to its at-the-market offering program, bitcoin holdings, share repurchase activity, and USD Reserve balance for the period ending August 9, 2026.
Powerfleet, Inc. filed a Current Report on Form 8-K on August 10, 2026, disclosing the issuance of a press release covering financial results for the fiscal quarter ended June 30, 2026, along with a slide presentation to accompany a same-day investor conference call.
Evolv Technologies Holdings, Inc. filed a Form 8-K on August 10, 2026, disclosing that a U.S. federal court granted preliminary approval on August 6, 2026, to a settlement resolving multiple stockholder derivative actions and a pre-suit demand against the company.
Archer Aviation Inc. filed a Current Report on Form 8-K on August 10, 2026, disclosing that on August 9, 2026, it entered into a definitive Equity Purchase Agreement with The Boeing Company to acquire three aviation-related subsidiaries in an all-equity transaction.
Beyond Meat, Inc. filed a current report on August 10, 2026, disclosing that it entered into a Second Supplemental Indenture amending its 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 indenture.
CoreCivic, Inc. filed a Form 8-K on August 10, 2026, disclosing that it entered into a $500.0 million accelerated share repurchase agreement on August 7, 2026, and issued a press release updating its full-year 2026 guidance.
Sight Sciences, Inc. filed a Form 8-K on August 10, 2026, disclosing the appointment of Kashif Rashid as Chief Legal Officer and Corporate Secretary and the concurrent departure of Jeremy Hayden from that role, both effective August 10, 2026.
Onto Innovation Inc. filed a current report on August 10, 2026, disclosing the completed acquisition of a 27% equity stake in Rigaku Holdings Corporation for approximately $720 million.
HBT Financial, Inc. filed a Form 8-K on August 10, 2026, disclosing that it entered into an Agreement and Plan of Merger with Tri-County Financial Group, Inc. on that same date.
Fulcrum Therapeutics, Inc. filed a Form 8-K on August 10, 2026, disclosing that its Board of Directors appointed Chief Financial Officer Alan Musso as principal accounting officer, effective August 7, 2026, following the departure of Greg Tourangeau from that role.